ADMA Biologics Net Income Over Time
| ADMA Stock | USD 17.52 0.02 0.11% |
With this module, investors can use any or all of fundamental ratio historical patterns as a complementary method for asset selection as well as a tool for deciding entry and exit points. Many technical investors use fundamentals to limit their universe of possible portfolio assets.
Check out ADMA Biologics Performance and ADMA Biologics Correlation. Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of ADMA Biologics. If investors know ADMA will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. Comprehensive ADMA Biologics assessment requires weighing all these inputs, though not all factors influence outcomes equally.
Earnings Share 0.81 | Revenue Per Share | Quarterly Revenue Growth 0.12 | Return On Assets | Return On Equity |
ADMA Biologics's market price often diverges from its book value, the accounting figure shown on ADMA's balance sheet. Smart investors calculate ADMA Biologics' intrinsic value - its true economic worth - which may differ significantly from both market price and book value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Since ADMA Biologics' trading price responds to investor sentiment, macroeconomic conditions, and market psychology, it can swing far from fundamental value.
Understanding that ADMA Biologics' value differs from its trading price is crucial, as each reflects different aspects of the company. Evaluating whether ADMA Biologics represents a sound investment requires analyzing earnings trends, revenue growth, technical signals, industry dynamics, and expert forecasts. However, ADMA Biologics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Cross Equities Net Income Analysis
Compare ADMA Biologics and related stocks such as ACADIA Pharmaceuticals, Praxis Precision Med, and Belite Bio ADR Net Income Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ACAD | (10.2 M) | (22.8 M) | (20.8 M) | (37.9 M) | (92.5 M) | (164.4 M) | (271.4 M) | (289.4 M) | (245.2 M) | (235.3 M) | (281.6 M) | (167.9 M) | (216 M) | (61.3 M) | 226.5 M | 203.8 M | 214 M |
| PRAX | (26.5 M) | (26.5 M) | (26.5 M) | (26.5 M) | (26.5 M) | (26.5 M) | (26.5 M) | (26.5 M) | (26.5 M) | (35.5 M) | (61.8 M) | (166.9 M) | (213.1 M) | (123.3 M) | (182.8 M) | (164.5 M) | (172.8 M) |
| BLTE | (5.8 M) | (5.8 M) | (5.8 M) | (5.8 M) | (5.8 M) | (5.8 M) | (5.8 M) | (5.8 M) | (5.8 M) | (5.8 M) | (5.8 M) | (9.7 M) | (12.6 M) | (31.6 M) | (36.1 M) | (32.5 M) | (30.9 M) |
| LGND | (27.1 M) | 10.2 M | (527 K) | 11.4 M | 12 M | 257.3 M | (1.6 M) | 12.6 M | 143.3 M | 629.3 M | (3 M) | 57.1 M | (33.4 M) | 52.2 M | (4 M) | (4.6 M) | (4.4 M) |
| SLNO | (6.5 M) | (6.5 M) | (6.5 M) | (3.7 M) | (13.9 M) | (15.9 M) | (12.1 M) | (15.7 M) | (13.3 M) | (30.8 M) | (24.6 M) | (30.9 M) | (24.1 M) | (39 M) | (175.8 M) | (158.3 M) | (150.4 M) |
| MIRM | (17.3 M) | (17.3 M) | (17.3 M) | (17.3 M) | (17.3 M) | (17.3 M) | (17.3 M) | (17.3 M) | (17.3 M) | (52.6 M) | (103.3 M) | (84 M) | (135.7 M) | (163.4 M) | (87.9 M) | (79.1 M) | (83.1 M) |
| DYN | 264 M | (1.6 B) | 87 M | (356 M) | (67 M) | 50 M | (1.2 B) | 76 M | (4.8 M) | (13.5 M) | (58.7 M) | (149.3 M) | (165.2 M) | (235.9 M) | (317.4 M) | (365 M) | (383.3 M) |
| CRNX | (6 M) | (6 M) | (6 M) | (6 M) | (6 M) | (6 M) | (6 M) | (9.2 M) | (27.1 M) | (49.5 M) | (72.9 M) | (106.7 M) | (160 M) | (214.5 M) | (298.4 M) | (268.6 M) | (255.1 M) |
| TLX | (289 K) | (2.5 M) | (2.5 M) | (2.5 M) | 5.4 M | (132 K) | (44 K) | (6.4 M) | (13.8 M) | (27.9 M) | (44.9 M) | (80.5 M) | (104.1 M) | 5.2 M | 49.9 M | 44.9 M | 47.2 M |
| RARE | (6.8 M) | (6.8 M) | (16.3 M) | (35.1 M) | (59.8 M) | (145.6 M) | (245.9 M) | (302.1 M) | (197.6 M) | (402.7 M) | (186.6 M) | (454 M) | (707.4 M) | (606.6 M) | (569.2 M) | (512.3 M) | (486.7 M) |
ADMA Biologics and related stocks such as ACADIA Pharmaceuticals, Praxis Precision Med, and Belite Bio ADR Net Income description
Net income is one of the most important fundamental items in finance. It plays a large role in ADMA Biologics financial statement analysis. It represents the amount of money remaining after all of ADMA Biologics operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue.My Equities
My Current Equities and Potential Positions
| ADMA Biologics | ADMA |
Specialization | Health Care, Pharmaceuticals, Biotechnology & Life Sciences |
| Business Address | 465 State Route |
| Exchange | NASDAQ Exchange |
USD 17.52
Check out ADMA Biologics Performance and ADMA Biologics Correlation. For information on how to trade ADMA Stock refer to our How to Trade ADMA Stock guide.You can also try the Global Correlations module to find global opportunities by holding instruments from different markets.
ADMA Biologics technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.